Navigation Links
Appointment of Dr. Ian Gilham as Chairman of the Board
Date:3/5/2013

LISBON, Portugal, March 5, 2013 /PRNewswire/ --

Biosurfit, a rapidly-growing company focused on the Point of Care medical diagnostic market, is pleased to announce today the appointment of Dr. Ian Gilham as Chairman of the Board.

Previously, Dr. Ian Gilham was Chief Executive Officer of Axis-Shield plc, the in-vitro diagnostics company acquired by Alere in November 2011 for £235M.  Whilst at Axis-Shield, Dr. Gilham held the position of Chief Operating Officer and became Chief Executive Officer in January 2008. Prior to its sale to Alere, Axis-Shield's revenues rose above £100M and the company issued a maiden dividend.  Before joining Axis-Shield, Dr. Gilham was VP Pharmacogenetics at GSK where he was responsible for the delivery of pharmacogentic tests, as well as novel diagnostic tests used in targeting GSK's medicines.  Prior to joining GSK, Dr. Gilham held international general management, marketing, business development and R&D positions with Abbott Laboratories, Celltech and Amersham, gaining wide expertise in the fields of pharmaceuticals and clinical diagnostics.

Commenting on his appointment, Dr. Ian Gilham , said: "I am delighted to join Biosurfit as Chairman of the Board. It is an incredibly exciting time for the company with new opportunities ahead and a chance to support an entrepreneurial team that have developed innovative and potentially game changing technologies into a great new product. Biosurfit has a tremendous potential in Point of Care Diagnostics with its spinit® instrument that is due to be launched in 2013. I look forward to working with the team to help Biosurfit in reaching its great ambitions."

João Garcia da Fonseca , Founder and CEO of Biosurfit, commented: "We are all delighted to have Ian join the team, particularly as we are preparing to launch our spinit® instrument in the Point of Care testing market. Ian is an experienced leader with an international track record in the research, development and commercialisation of diagnostic and pharmaceutical products. His wealth of experience and great knowledge of the IVD industry will be extremely valuable to Biosurfit."

About Biosurfit

Biosurfit is a Venture Capital backed diagnostics company founded in 2006. The company invented and developed breakthrough technologies that enable fast, precise and affordable blood analysis, aiming for the key parameters that doctors really want. These proprietary technologies are combined in the spinit® instrument, using a user-friendly reader and disposable disk cartridges for specific clinical conditions. The spinit® instrument uses only one drop of blood to deliver precise results within 10-15 minutes. Initial disposable cartridges to be launched in 2013 include CRP, Blood Count and an Inflammation Panel. It is planned that future tests will include diabetes and cardiac multi-parameter panels.

For more information, please contact:

João Garcia da Fonseca , CEO of Biosurfit, tel: +351-217500228

Mary-Jane Elliott or Claire Dickinson , M:Communications, tel: +44(0)20-7920-2345



'/>"/>
SOURCE Biosurfit
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Denver Patients Can Now Easily Find Doctors and Schedule Appointments Online
2. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
3. American Oriental Bioengineering Announces Appointment of Audit Committee Chairman
4. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
5. OceanGate Inc. Expands Board of Directors with Two Key Appointments
6. Aethlon Medical Announces the Appointment of Thomas V. Wornham and Philip A. Ward to its Board of Directors
7. ADVENTRX Announces Appointment Of Chief Medical Officer
8. Aragon Pharmaceuticals Announces Appointment of Faheem Hasnain as Independent Director
9. ADVENTRX Announces Appointment Of Ted W. Love M.D. To Board Of Directors
10. H. D. Smith Names Timothy Booth Corporate VP, Home Healthcare (HHC), In First-of-its-Kind Leadership Appointment
11. Simcere Pharmaceutical Group Announces Appointment of New Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017   Pulmatrix, Inc . (NASDAQ: ... to address serious pulmonary diseases, today announced that it has ... cystic fibrosis and asthma to its Scientific Advisory Board ... Richard B. Moss , MD, former chief of ... the Cystic Fibrosis Center at Stanford University, and ...
(Date:3/27/2017)... , March 27, 2017 On ... the NASDAQ Composite closed the trading session up 0.19%; ... the S&P 500 was down 0.08%. US markets made ... finishing the day in green. Pre-market today, Stock-Callers.com reviews ... Group N.V. (NASDAQ: WMGI), Amedica Corporation (NASDAQ: AMDA), MiMedx ...
(Date:3/27/2017)... March 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today ... Paul M. Bisaro as Impax,s President and Chief ... effective March 27, 2017. Mr. Bisaro will succeed ... President and Chief Executive Officer since December of 2016. ... branded pharmaceutical experience, Mr. Bisaro, 56, is an accomplished ...
Breaking Medicine Technology:
(Date:3/28/2017)... San Francisco, CA (PRWEB) , ... March 28, 2017 , ... ... restoration treatment, is proud to announce a new blog post about women’s hair loss. ... women suffer from hair loss as they age. Menopause or genetics can be two ...
(Date:3/28/2017)... Louis, MO (PRWEB) , ... March 28, 2017 ... ... levels of job satisfaction in their profession as their value increases in the ... company that provides resources such as job boards, career fairs, and candidate leads ...
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who want to experience the benefits ... now have them placed by Dr. Manju Kejriwal, with or without a referral. Dr. ... increase the accuracy of each dental implant placement. The i-CAT CBCT system captures the ...
(Date:3/27/2017)... ... March 27, 2017 , ... This ... OSEHRA popHealth Community in 2014. It is the culmination of collaborative ... Open Source Project Group. OSEHRA Organizational Member Zato Health co-funded the ONC certification ...
Breaking Medicine News(10 mins):